MSC Neuroregeneration Program
Mesenchymal stem cell therapies for neurodegenerative disease — secreted bioactive factors for repair and anti-inflammation.
The problem we are solving.
Mesenchymal stromal cells do something no drug can: they secrete a dynamic cocktail of growth factors, anti-inflammatory mediators, and regenerative signals calibrated to the tissue they arrive in. For the central nervous system, where inflammation compounds damage and repair is notoriously difficult, this biological intelligence is uniquely valuable.
The challenge has never been the biology of the cells themselves — it has been delivery, dose consistency, and the logistical burden of maintaining viable cells through the cold chain to the patient. MACRO HRD's contribution is to those barriers, not to the underlying mechanism.
How we tackle it.
The MSC Neuroregeneration program brings together three platform capabilities: Immune Cell Banking for source-material standardization and traceability, Ambient Cell Logistics for room-temperature delivery without DMSO-based cryopreservation, and GEDM-3DQ for monitoring patient response trajectories post-administration.
The therapeutic intent spans neurodegenerative conditions where chronic inflammation drives progressive damage — including target indications informed by partnerships with the Brain Mapping platform and the Huntington's Disease program. Delivery routes under evaluation include intrathecal and stereotactic administration, depending on indication and disease stage.
What makes this real.
Part of an integrated platform.
“The cells already know what to do. Our job is to get them there, intact.”